| ID | 1230 |
| Name of the vaccine | Chloroform-methanol residue (CMR) |
| Microbe | Bacteria |
| Disease name | Q Fever |
| Name of bacteria | Coxiella burnetii |
| Type of vaccine | Inactivated |
| Nucleic acid content | Linear DNA |
| Age | NA |
| Description of the vaccine | Chloroform-methanol residues from killed whole cells of C. burnetii. |
| Name of the manufacturer | NA |
| Name of the manufacturing country | NA |
| Year of manufacture | NA |
| Clinical Phase status | Clinical |
| Bacterial strain | Gram-negative bacterium. |
| Efficacy | NA |
| Vaccine formulation | NA |
| Dosage | Single dose of 30, 60, 120, or 240 micrograms. |
| Mechanism of action | Serum immunoglobulin M response, G response and peripheral blood T-cell proliferative response. |
| Route of administration | Subcutaneous |
| Indications | NA |
| Export | NA |
| Approval | NA |
| Adjuvant | NA |
| Repurposing | NA |
| Side effects of vaccine | Transient discomfort, erythema, induration, malaise and low-grade fever |
| Post vaccination | NA |
| Dose type | Single dose |
| Interspecies transfer | Yes (by inhaling dust particles contaminated by infected animals) |
| PubMed identifier | 8454328 |
| Clinical trial number | NA |
| Reference | http://www.violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=241&keywords= |
| Other name | NA |
| Additional Links | NA
|